Can Novartis' CEO resist going for a megamerger with cash from asset sales?
admin 30th May 2017 Uncategorised 0A series of potential asset deals could put $50 billion cash in the hands of Novartis CEO Joe Jimenez. While he has said he is looking for manageable deals, the company’s pharma portfolio has gaping holes, and some analysts are getting anxious the Swiss pharma might squander its opportunity as it did when it bought Alcon, one of the operations Jimenez might unload.
More: Can Novartis' CEO resist going for a megamerger with cash from asset sales?
Source: fierce